Summary:
A double-blind, placebo-controlled, dose escalation study of five weekly intravenous infusions of a new study medication to evaluate the safety and tolerability upon repeat administration.
Qualified Participants Must:
• Be between 18 and 70 years of age
•
Have been diagnosed with SLE
•
Be stable on current treatment for SLE with no history of cancer